Events & Presentations
Date | Event Details | Remind Me |
---|---|---|
Apr 3 - Apr 4, 2023
|
7th Complement UK Training Course and Symposium
|
Date | Event Details |
---|---|
May 7, 2020 4:30 PM EDT
|
Arrowhead Pharmaceuticals 2020 Second Quarter Results
Prepared Remarks 210.2 KB
|
Mar 18, 2020 4:00 PM EDT
|
Oppenheimer 30th Annual Healthcare Conference
New York
Conference Presentations cancelled due to COVID-19 |
Mar 17, 2020 2:00 PM EDT
|
5th Annual Oligonucleotide & Precision Therapeutics Congress
Cambridge
Conference Presentations cancelled due to COVID-19 |
Mar 11, 2020 11:15 AM EDT
|
Barclays Global Healthcare Conference
Miami
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will participate in a hybrid podium/fireside chat presentation
|
Feb 5, 2020 4:30 PM EST
|
Arrowhead Pharmaceuticals 2020 First Quarter Results
|
Dec 10, 2019 6:00 PM HST
|
HEP DART 2019
View Presentation 6.4 MB
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “Where will RNAi fit in the era of finite therapies” |
Dec 3, 2019 11:00 AM EST
|
Piper Jaffray 31st Annual Healthcare Conference
Fireside chat cancelled
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation with Edward Tenthoff, managing director and senior research analyst at Piper Jaffray |
Nov 25, 2019 4:30 PM EST
|
Arrowhead Pharmaceuticals 2019 Year End Results
Prepared Remarks 191.4 KB
|
Nov 18, 2019
|
American Heart Association Scientific Sessions 2019
Philadelphia
November 18, 9:32 a.m. EST – Dr. Christie Ballantyne, Baylor Coll Med, Houston, TX, will deliver an oral presentation titled, “RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides” November 18, 9:38 a.m. EST – Dr. Gerald Watts, Univ of Western Australia, Royal Perth Hosp, Perth, Australia, will deliver an oral presentation titled, “RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects” |
Nov 8 - Nov 12, 2019
|
The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
Boston
Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B
FIRST CLINICAL EXPERIENCE WITH RNA INTERFERENCE [RNAi]-BASED TRIPLE COMBINATION THERAPY IN CHRONIC HEPATITIS B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) AND A NUCLEOS(T)IDE ANALOGUE (NA)
|